论文信息 - Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study - 字舞流文

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

K. de Heer | K. Nasserinejad | P. Sonneveld | M. Vekemans | N. Thielen | D. Issa | L. Tick | M. Levin | S. Klein | E. van der Spek | P. Ypma | S. Zweegman | N. V. D. van de Donk | M. Sohne | K. Wu | I. Nijhof | I. Ludwig | G. Velders | M. Leijs | M. Westerman | C. Stege | M. Seefat | R. V. van Kampen | E. D. de Waal | F. Croon-de Boer | G. Timmers | K. Groen